Key result
TMVR for MAC or failing rings achieves ~63% technical success and reduces mitral valve gradients.
Why the study?
TMVR is evolving as a treatment option for severe mitral annular calcification and failing ring repairs, but the use of adjunctive techniques like anterior mitral leaflet laceration and alcohol septal ablation is not well studied in clinical practice.
Observational (n=40)
No
Transcatheter mitral valve replacement for mitral annular calcification or failing rings is feasible and reduces mitral valve gradients, but it is associated with significant procedural risks and frequently requires complex adjunctive techniques.
Answers are grounded in this paper and cite their sources.
TMVR with adjunctive LAMPOON and pre-emptive ASA shows moderate technical success in high-risk ViMAC/ViRing cases; leaves open the need for dedicated devices and prospective trials.
OBJECTIVES: The aim of this study was to evaluate outcomes of commercial transcatheter mitral valve replacement (TMVR) for annular rings and calcification using contemporary techniques. BACKGROUND: TMVR is evolving in the absence of other viable treatment options for severe mitral annular calcification and failing ring repairs. The concomitant use of laceration of the anterior mitral valve leaflet to prevent left ventricular outflow tract obstruction and pre-emptive alcohol septal ablation is not well studied in clinical practice. METHODS: A single-center study was conducted of valve-in-mitral annular calcification (ViMAC) and valve-in-ring (ViRing) TMVR from September 2015 to April 2020. In-hospital and 30-day outcomes were assessed. RESULTS: Forty patients underwent TMVR (28 ViMAC and 12 ViRing). Sixteen ViMAC (57%) and 5 ViRing (42%) patients underwent attempted laceration of the anterior mitral valve leaflet to prevent left ventricular outflow tract obstruction. Three patients underwent pre-emptive alcohol septal ablation. The median index hospitalization was 7 days. Six patients died within 30 days of the procedure, 6 (21%) in the ViMAC group and none in the ViRing group. Five patients (13%) had left ventricular outflow tract obstruction: 4 (14%) in the ViMAC cohort and 1 (8%) in the ViRing cohort. Five patients (13%) had either intraprocedural valve embolization or late migration (4 ViMAC and 1 ViRing). Technical success defined according to Mitral Valve Academic Research Consortium criteria was present in 25 patients (63%): 9 (75%) in the ViRing cohort and 16 (57%) in the ViMAC cohort. At 30 days, the mitral valve gradient was significantly reduced (5.5 ± 2.1 vs. 10.6 ± 4.8; p < 0.01). Three patients (8%) had at least moderate residual mitral regurgitation. CONCLUSIONS: Transcatheter ViMAC and ViRing can be successfully performed but frequently require the use of contemporary adjunctive techniques.
No takes yet. Share an insight, caveat, or question.
Tiwana et al. (2020) conducted an observational in Severe mitral annular calcification and failing ring repairs (n=40). Transcatheter mitral valve replacement (TMVR) was evaluated on Technical success according to Mitral Valve Academic Research Consortium criteria. Transcatheter mitral valve replacement for mitral annular calcification or failing rings achieved technical success in 63% of patients and reduced the mitral valve gradient.
Synapse has enriched 10 related papers. Consider them for comparative context: